Table 1 Baseline characteristics for patient strata according to quartiles of BNP
Quartiles of BNP, pg/mL | |||||
|---|---|---|---|---|---|
Characteristics | < 33.0 | 33.0–96.0 | > 96.0–310.0 | > 310.0–4001.0 | P value |
Demographics | |||||
Age, y* | 56.6 ± 13.4 | 67.8 ± 12.8 | 75.5 ± 10.7 | 78.4 ± 9.8 | 0.000 |
Female gender, % (n) | 30.0 (62) | 37.4 (77) | 45.7 (95) | 43.0 (89) | 0.006 |
Risk markers at baseline | |||||
TnT > 0.05 (ng/mL), % (n) | 34.8 (72) | 41.7 (86) | 42.3 (88) | 58.5 (121) | 0.000 |
hsCRP* (mg/L) | 7.3 ± 16.7 | 11.2 ± 31.8 | 21.5 ± 60.0 | 32.0 ± 66.7 | 0.000 |
Risk factors | |||||
Hypercholesterolemia, % (n) | 45.4 (94) | 58.3 (120) | 49.3 (102) | 45.4 (94) | 0.028 |
Total cholesterol (mmol/L)* | 5.6 ± 1.2 | 5.2 ± 1.3 | 5.2 ± 1.3 | 4.9 ± 1.3 | 0.000 |
HDL cholesterol (mmol/L) * | 1.3 ± 0.4 | 1.4 ± 0.5 | 1.4 ± 0.4 | 1.4 ± 0.5 | 0.305 |
Triglycerides (mmol/L) * | 1.9 ± 1.6 | 1.6 ± 1.3 | 1.5 ± 0.9 | 1.4 ± 0.8 | 0.000 |
Current smoking, % (n) | 41.5 (86) | 25.2 (52) | 19.2 (40) | 19.3 (40) | 0.000 |
Hypertension, % (n) | 26.6 (55) | 44.2 (91) | 48.6 (101) | 50.2 (104) | 0.000 |
IDDM, % (n) | 1.0 (2) | 0.5 (1) | 1.9 (4) | 0.5 (1) | 0.393 |
NIDDM, % (n) | 5.8 (12) | 14.1 (29) | 14.4 (30) | 15.5 (32) | 0.010 |
eGFR* (ml/min/1.73 m2) | 74.2 ± 17.6 | 66.3 ± 17.5 | 58.7 ± 20.3 | 50.9 ± 20.3 | 0.000 |
History of heart failure | |||||
CHF, % (n) | 6.8 (14) | 14.6 (30) | 27.9 (58) | 57.5 (119) | 0.000 |
NYHA (I/II/III/IV), n | 2/8/4/0 | 5/18/6/1 | 9/30/18/1 | 13/51/53/2 | 0.000 |
History of coronary heart disease | |||||
Angina pectoris, % (n) | 30.9 (64) | 42.7 (88) | 48.1 (100) | 52.7 (109) | 0.000 |
MI, % (n) | 15.0 (31) | 30.1 (62) | 38.5 (80) | 48.3 (100) | 0.000 |
CABG, % (n) | 6.3(13) | 12.1 (25) | 9.6 (20) | 12.6 (26) | 0.128 |
PCI, % (n) | 7.2 (15) | 14.6 (30) | 10.6 (22) | 8.7 (18) | 0.080 |
Treatment prior to admission | |||||
Statins, % (n) | 26.1 (54) | 41.3 (85) | 34.6 (72) | 34.8 (72) | 0.014 |
Clopidogrel, % (n) | 1.0 (2) | 2.9 (6) | 1.0 (2) | 2.9 (6) | 0.249 |
β-blocade, % (n) | 16.4 (34) | 38.3 (79) | 42.8 (89) | 45.9 (95) | 0.000 |
ACE inhibitors, % (n) | 10.6 (22) | 16.0 (33) | 21.2 (44) | 27.1 (56) | 0.000 |
ARB, % (n) | 6.3 (13) | 19.4 (40) | 17.3 (36) | 20.8 (43) | 0.000 |
Diuretics, % (n) | 12.1 (25) | 20.4 (42) | 36.5 (76) | 55.1 (114) | 0.000 |
Index diagnosis | |||||
STEMI, % (n) | 18.4 (38) | 18.4 (38) | 11.1 (23) | 11.6 (24) | 0.042 |
NSTEMI, % (n) | 15.9 (33) | 23.8 (49) | 31.3 (65) | 46.9 (97) | 0.000 |
UA, % (n) | 2.4 (5) | 4.9 (10) | 13.9 (29) | 15.5 (32) | 0.000 |
No-ACS, % (n) | 63.3 (131) | 52.9 (109) | 43.8 (91) | 26.1 (54) | 0.000 |